Adjuvant anti-PD-1 therapy (nivolumab or pembrolizumab) has demonstrated a significant recurrence-free survival benefit over both ipilimumab (CTLA-4 inhibitor) and placebo in resected stage III–IV melanoma across multiple prospective, randomised phase III trials [33,34]. Here, PDCD1 is linked to melanoma.